PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT—NONEXCLUSIVE COVER PAGEPatent License Agreement • June 5th, 2006 • Neopharm Inc • Biological products, (no disgnostic substances) • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) and/or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D. (Modifications), Appendix E (Benchmarks), and Appendix F (Commercial Development Plan). The Parties to this Agreement are:
License AmendmentNeopharm Inc • June 5th, 2006 • Biological products, (no disgnostic substances)
WHEREAS, the National Institutes of Health (“NIH”), on behalf of the Public Health Service (“PHS”) and the Department of Health and Human Services (“DHHS”), and NeoPharm, Inc. (“Licensee”) entered into license agreement (L-226-1996/0; the “Agreement”) effective September 23, 1997 under which HHS Ref. E-266-1994/0 corresponding to U.S. Patent 5,614,191; U.S. Patent 5,919,456; U.S. Patent 6,518,061; U.S. Patent Application 10/318,608, European Patent Application 96909693.2, Australian Patent 714,541, Canadian Patent Application 2215122, and Japanese Patent Application 8-528499 entitled “IL-13 Receptor Specific Chimeric Proteins And Uses Thereof,” were exclusively licensed and U.S. Patent 4,892,827 entitled “Recombinant Pseudomonas Exotoxins: Construction Of An Active Immunotoxin With Low Side Effects,” was licensed non-exclusively as background rights.
